Company to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea’s neoantigen-targeted peripheral T cell therapy for solid tumors
The PLANET manufacturing process reliably generates abundant, high-quality neoantigen-specific T cells
Preclinical data indicate that Inhibigens™ accelerate tumor growth in animal models of pancreatic cancer and melanoma